Risk estimates for most genes were slightly diminished when including only those patients with PC for whom PC was the first cancer diagnosis, although MSH2 and TP53 mutations were no longer significantly associated with moderate risk of PC because of the decreased number of mutations in patients with PC, and the modest OR associated with CHEK2 was marginally significant (Appendix Table A9). This evidence concerns the gene TP53 and cancer.